Comparison of Methods to Generalize Randomized Clinical Trial Results Without Individual-Level Data for the Target Population
暂无分享,去创建一个
Stephen R Cole | Til Stürmer | Michele Jonsson Funk | Michael Webster-Clark | Jin-Liern Hong | Sara E Dempster | Iksha Herr | Robert LoCasale | S. Cole | T. Stürmer | R. LoCasale | M. Jonsson Funk | Michael Webster-Clark | S. Dempster | Jin-Liern Hong | I. Herr | Michele Jonsson Funk | Michael A Webster-Clark
[1] Jeffrey A. Smith,et al. Does Matching Overcome Lalonde's Critique of Nonexperimental Estimators? , 2000 .
[2] Patrick Royston,et al. The cost of dichotomising continuous variables , 2006, BMJ : British Medical Journal.
[3] Stephen H Bell,et al. External Validity in Policy Evaluations that Choose Sites Purposively. , 2013, Journal of policy analysis and management : [the journal of the Association for Public Policy Analysis and Management].
[4] Ingeborg Waernbaum,et al. Correlation and efficiency of propensity score-based estimators for average causal effects , 2015, Commun. Stat. Simul. Comput..
[5] S. Cole,et al. Generalizing Randomized Clinical Trial Results: Implementation and Challenges Related to Missing Data in the Target Population , 2018, American journal of epidemiology.
[6] J. Caro,et al. Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events. , 1999, The American journal of medicine.
[7] Mei Lu,et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[8] S. Cole,et al. Generalizing evidence from randomized clinical trials to target populations: The ACTG 320 trial. , 2010, American journal of epidemiology.
[9] S. Cole,et al. Practice of Epidemiology Estimation of the Standardized Risk Difference and Ratio in a Competing Risks Framework : Application to Injection Drug Use and Progression to AIDS After Initiation of Antiretroviral Therapy , 2015 .
[10] J. Dalton,et al. A unified approach to measuring the effect size between two groups using SAS , 2012 .
[11] Paul M. Ridker,et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein , 2009 .
[12] Peter Sandercock,et al. Interpretation of the evidence for the efficacy and safety of statin therapy , 2016, The Lancet.
[13] Stephen R Cole,et al. Transportability of Trial Results Using Inverse Odds of Sampling Weights. , 2017, American journal of epidemiology.
[14] Catherine P. Bradshaw,et al. The use of propensity scores to assess the generalizability of results from randomized trials , 2011, Journal of the Royal Statistical Society. Series A,.
[15] M. Stuart,et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein (CRP) , 2009 .
[16] Robert J. Glynn,et al. Rosuvastatin for Primary Prevention in Older Persons With Elevated C-Reactive Protein and Low to Average Low-Density Lipoprotein Cholesterol Levels: Exploratory Analysis of a Randomized Trial , 2010, Annals of Internal Medicine.
[17] Sofia Dias,et al. Methods for Population-Adjusted Indirect Comparisons in Health Technology Appraisal , 2017, Medical decision making : an international journal of the Society for Medical Decision Making.
[18] Daniel F. McCaffrey,et al. Comment: Demystifying Double Robustness: A Comparison of Alternative Strategies for Estimating a Population Mean from Incomplete Data , 2008, 0804.2962.
[19] T. VanderWeele,et al. Evaluating Public Health Interventions: 7. Let the Subject Matter Choose the Effect Measure: Ratio, Difference, or Something Else Entirely , 2018, American Journal of Public Health.
[20] Eric Q. Wu,et al. Comparative Effectiveness Without Head-to-Head Trials , 2012, PharmacoEconomics.
[21] C. Drake. Effects of misspecification of the propensity score on estimators of treatment effect , 1993 .
[22] P. Ridker,et al. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. , 2010, Journal of the American College of Cardiology.
[23] Jennifer Hill,et al. Assessing Methods for Generalizing Experimental Impact Estimates to Target Populations , 2016, Journal of research on educational effectiveness.